Rethinking the Role of Liver Biopsy in the Era of Personalized Medicine by Casanovas Taltavull, Teresa
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 3
Rethinking the Role of
Liver Biopsy in the Era of Personalized Medicine
Teresa Casanovas Taltavull
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/53120
1. Introduction
Indications and methods of liver biopsy have changed over the past few years [1]. However,
an histological diagnosis may be needed for optimal management of a patient [2, 3].
Although modern biochemical, immunological, and radiographic techniques have facilitat‐
ed the diagnosis and management of liver diseases they have not made liver biopsy obso‐
lete. Clinicians rely on information derived from the liver biopsy to inform patients and to
make their therapeutic options [4].
There are, however, many controversies surrounding liver biopsy resulting potential limita‐
tions, such as sampling errors and interobserver variations [5], which can lead to misclassifi‐
cation therefore, P. Bedossa et al. consider that when it comes to liver biopsy the term ‘‘best”
standard is more appropriate than ‘‘gold” standard [6].
It is essential, when analysing the indications, contraindications, complications and other as‐
pects of the liver biopsy, to consider present hepatology and personalized medicine.
Practiced since  the  late  19th  century,  liver  biopsy remains  the  criterion standard in  the
evaluation of the etiology and extent of disease of the liver. Paul Ehrlich performed a per‐
cutaneous  liver  biopsy  in  Germany  in  1883.  [7].  Since  then,  this  method  has  been  im‐
proved  with  the  introduction  of  different  needle  types  for  cutting  and  aspiration.  But,
until the 1950s, when Menghini developed an aspiration technique which led to a wider
use of the procedure and broadened its applications, it was not common. While in the ear‐
ly 1960 and 1970s the liver biopsy was used for making a diagnosis in cases of suspected
medical liver disease, today it is more often performed to assess the prognosis or evaluate
therapeutic strategies [1].
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With regards to the technique used to carry out the liver biopsy there has also been a major
change, it used to be performed blindly by clinicians, specialists in gastroenterology or hep‐
atology at the patient’s bed whereas at present, percutaneous biopsies are performed pri‐
marily by radiologists.
Currently, a liver biopsy can be obtained either transvenously or transcutaneously, or by
combining imaging modalities such as ultrasound, computed tomography, and laparosco‐
py. The choice of one technique over another is based on availability, personal preference,
and the clinical situation.
Liver biopsy techniques: Percutaneous, transjugular or laparoscopic
• Percutaneous liver biopsy can be transthoracic, with an intercostal liver access or subcos‐
tal, when the patient has an enlarged liver extending below the costal margin. Clinicians
have now discarded blind liver biopsies in favour of ultrasound-guided biopsies.
• Transjugular or transvenous liver biopsy was first described in 1964. It is a technique used
in order to avoid percutaneous liver biopsy in patients who are at a higher risk of bleed‐
ing. However, it has its limitations and is considered an inferior biopsy due to the frag‐
mentation of the obtained specimen, which may reduce the accuracy of the diagnosis. It is
performed in a vascular catheterisation laboratory by a radiologist with special training in
interventional radiology. Videofluoroscopy equipment and cardiac monitoring are man‐
datory due to the risk of cardiac arrhythmia as the catheter passes through the right at‐
rium. With this method, hepatic venography, wedged hepatic venous pressure, caval
pressure and atrial pressure measurements can also be obtained during the procedure.
The most frequent indications for the transjugular route are: severe coagulopathy, ascites,
obesity, suspected vascular tumour or peliosis hepatis.
• Laparoscopic liver biopsy. This technique is well established and its use varies between
centers. It is indicated in centers where access to transvenous liver biopsy is not available,
and in patients with focal liver lesions and coagulopathy for whom obtaining histology is
essential for their management.
The decision to use a particular technique is based on the risk profile of the patient. If he or
she has advanced liver failure with coagulopathy and ascites, liver biopsy is unnecessary,
but the diagnosis of the underlying disease is crucial in specific circumstances in order to
determine a therapy, for example in cases of liver transplant. Before a liver biopsy it is nec‐
essary to carry out an ultrasound to quantify vascular permeability and because it may rule
out anatomical abnormalities and can identify mass lesions that are clinically silent. When
cirrhosis is suspected on clinical grounds, or by non-invasive methods liver biopsy is usual‐
ly avoided.
2. Contraindications to percutaneous liver biopsy
Absolute  contraindications:  the  main  contraindication  to  percutaneous  liver  biopsy  is
significant coagulopathy, others are: uncooperative patient, history of unexplained bleed‐
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ing,  prothrombin  time  3–5  seconds  more  than  control,  platelet  count  less  than  50,000/
mm3,  the  use  of  a  non-steroidal  anti-inflammatory  drugs,  (unless  discontinued  7  to  10
days previously), blood for transfusion unavailable, suspected hemangioma, another vas‐
cular tumor or echinococcal cysts in the liver, and the inability to identify an appropriate
site for biopsy.
Relative contraindications: Morbid obesity, ascites, hemophilia, infection in the right pleu‐
ral cavity or below the right hemidiaphragm.
Accepted indications: Given the new developments that have proved the efficacy of liver
biopsy, its role in the management of patients with chronic liver diseases has much evolved
in recent years and will continue to evolve as new non invasive technologies are developed.
• Diagnosis
1. Many parenchimal liver diseases
2. Abnormal liver tests
3. Fever of unknown origin
4. Focal or diffuse abnormalities on imaging studies
• Prognosis-Staging of known parenchimal disease
• Management –Developing treatment plans based on histologic analysis
Contraindications for percutaneous liver biopsy
• Absolute: uncooperative patient, severe coagulopathy, infection of the hepatic bed, extrahepatic biliary obstruction.
• Relative: ascites, morbid obesity, possible vascular lesions, amyloidosis, hydatid disease.
Table 1. Indications and contraindications for liver biopsy
Its importance in diagnosis, staging and prognosis largely depends on the indication and the
clinical question relying on an answer from the histological result.
2.1. Is liver biopsy always necessary?
The utility of routine liver biopsy has been the subject of debate in recent years. Due to liver
biopsy being associated with a small but definite risk, a biopsy should only be performed
when the findings contribute to a better management of the patient. It is argued that for the
purposes of management, liver biopsy is neither needed in cases with advanced fibrosis nor
those diagnosed with cirrhosis by other methods, nor in patients with mild disease, for
whom a therapeutic decision is not urgent. Until recently, liver biopsy played a key role in
the evaluation of chronic liver disease, but now in the presence of better diagnostic tests on
disease etiologies and treatments its role has to be re-evaluated. Recognition and confirma‐
tion of the pattern of injury (chronic hepatitic, chronic cholestatic, steatohepatitic, etc.) is the
pathologist's priority when evaluating the liver biopsy.
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Moreover, liver biopsy provides information on the severity and distribution of lesions (co‐
dified in the staging and grading of chronic liver disease), the presence of confounding pat‐
terns of injury (such as steatohepatitis coexisting with chronic viral hepatitis), and the
presence of additional findings such as steatosis or iron accumulation that may have prog‐
nostic or therapeutic relevance.
2.2. Who should be biopsied?
As a rule patients with standard clinical and radiological features are not biopsied. Howev‐
er, in the presence of non concordant or atypical results, a biopsy may be recommended.
The decision whether to perform a liver biopsy in some patients is clear, however in cases
with a suspected concomitant diagnosis or when results from other methods are non conclu‐
sive confirmation is needed [8,9].
Type of Injury Causes
Fatty change Ethanol, fatty liver disease, obesity, diabetes, drugs
Councilman bodies Viral hepatitis, drugs, toxins, ischemia (acidophilic bodies)
Mallory bodies * (hyaline)
(see pages: 13, 15, 17 and 18)
Ethanol, obesity, diabetes, drugs, Wilson disease, biliary
tract disease, hepatocellular carcinoma
Hydropic change (ballooning degeneration) Viral hepatitis, drugs, cholestasis, fatty liver disease
Cholestasis Duct obstruction or injury, drugs, viral hepatitis
Interlobular duct injury Primary biliary cirrhosis, primary sclerosing cholangitis,
hepatitis C
Piecemeal necrosis Viral hepatitis, primary biliary cirrhosis, drugs, Wilson
disease
Increased iron stores Hemochromatosis, transfusions, hemolysis
Granulomas**
(see pages: 19, 20 and 21)
Sarcoid, infections (tuberculosis, fungi), drugs
Table 2. Patterns of liver cell injury found in liver biopsies and clinical differential diagnosis
3. The generally accepted indications of liver biopsy are the following
• Diagnosis for a better scoring of grading and staging of chronic viral hepatitis C or hepati‐
tis B, alcoholic liver disease, non-alcoholic steato-hepatitis, or autoimmune hepatitis.
• In patients with raised ferritine for the diagnosis of hemochromatosis
• If there are suspected disorders of cupper metabolism for the diagnosis of Wilson’s dis‐
ease, with quantitative estimation of copper in liver tissue.
• Evaluation of possible autoimmune hepatitis
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• In cholestatic liver diseases: primary biliary cirrhosis, primary sclerosing cholangitis and
overlap syndromes.
• Evaluation of abnormal results of biochemical tests of the liver in association with a sero‐
logic workup that is negative or inconclusive
• Evaluation of the efficacy or the adverse effects of treatment regimens (e.g.,methotrexate
therapy for psoriasis).
• Alcohol related disease. Non-alcoholic fatty liver disease (NAFLD) or Non-alcoholic stea‐
tohepatitis (NASH).
• Diagnosis of a liver mass, in selected cases, when image tests are inconclusive.
• Evaluation of fever of unknown origin, with an eventual culture of liver tissue.
• Evaluation of the status of the liver post transplantation or of the donor liver pre trans‐
plantation.
4. Methods: How to handle a liver biopsy
Liver samples should be fixed in 10% neutral buffered formalin because this enables all rou‐
tine histochemical and immunohistochemical staining to be carried out. A small portion of
the sample could be snap-frozen for adjunctive molecular studies for diagnostic or research
purposes, particularly when multiple etiologies are clinically suspected.
As for stains, a good collagen stain to assess fibrosis is mandatory. Perls’ stain for iron is rec‐
ommended and the Periodic Acid-Schiff (PAS) stain with and without diastase digestion is
useful for assessing hepatocyte cytoplasm glucogen content.
Special stains for special circumstances are ordered if indicated by the clinical situation. For
instance, the Ziehl-Nielsen is ordered for mycobacteria, and Grocott’s silver methanamine
stain is used when granulomas are observed or when fungi infection is suspected. The Con‐
go Red stain is requested when amyloid is suspected to be present Rhodamine stain, Victo‐
ria blue or orcein stain is used to detect copper deposition when there is clinical suspicion of
Wilson’s disease. Immunohistochemistry is used to confirm the presence of Hepatitis B sur‐
face antigen and Hepatitis B core antigen [10].
Cultures could be indicated in selected cases such as Mycobacterias [11].
5. Histologic diagnosis and clinical correlation
The pathological report that used to be too descriptive now has to include etiology, aspects
related to prognosis and possible therapy [12,13].
In order to promote the clinico-pathological diagnostic correlation with the intention of im‐
proving communication and clarifying individual cases, regular meetings between clinicians
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and pathologists are necessary. It is not only important to hold formal conferences but also to
increase daily exchanges. To facilitate the communication between pathologists, radiologists,
surgeons and clinicians it is desirable, when feasible, for the same teams to work together.
6. Writing the histology report
In order to produce a clinically relevant liver histology report pathologists should follow the
internationally accepted guidelines.
1. The adequacy of the biopsy should be assessed by measuring the length of the speci‐
men and counting the number of portal tracts. The data should be written up in the fi‐
nal report to make clinicians aware of any potential sampling error in the grading and
staging. To reduce sampling error the amount of tissue required is usually 1 to 4 cm
long and needs to include at least four portal tracts.
2. The type and severity of necroinflammation and fibrosis should be described in words.
By only using numbers to report the presence or not of bridging necrosis for example,
some clinically useful information might be omitted. A validated scoring system should
be used for grade of activity and stage of fibrosis.
3. As well as being described, the existence of adjunt data should be scored subjectively,
such as steatosis graded on a scale of 0-3 and siderosis graded on a scale of 0-4.
4. Other diagnostic criteria may be useful in differential diagnoses:
• Differentiating viral hepatitis from other chronic disorders, such as cell dysplasia and
thus separately reporting the presence of cell changes.
• Using immunostaining when appropriate, for example Hepatitis B Virus antigens
[14].
• Searching for any concomitant diseases.
5. Chronic viral hepatitis, primary biliary cirrhosis and autoimmune hepatitis have typical
histological lesions and it is advisable to consider the characteristics of: portal tract in‐
flammation, interface hepatitis, lobular necrosis and bile duct damage, separately [15].
6. Concomitant histological features in liver specimens of hepatitis C cases: auto-immuni‐
ty, co-infections, steatosis, hemosiderosis, malignancy –related changes, hepatitis due to
drugs and/or vascular problems. Furthermore, biopsy frequently detects associated le‐
sions such as steatosis or steatohepatitis providing information related to management
and prognosis of patients with chronic hepatitis C.
7. Finally the conclusions should be written in order to make the histological diagnosis,
stating whether the pathological findings are consistent with chronic hepatitis or not,
whether a specific viral etiology may be suspected or whether there are changes related
to concomitant diseases, specifying which.
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Chronic viral hepatitis Primary Biliary Cirrhosis (PBC) Autoimmune Hepatitis
Portal tract
inflammation
Mononuclear cells Mononuclear cells; eosinophils Mononuclear cells;
plasma cells
Interface hepatitis Common Common;ductular reaction
(i.e. biliary piecemeal necrosis)
Present
Lobular necrosis Variable degree usually focal Variable; usually mild and focal Severe, may be confluent
Bile duct damage Common in hepatitis C
(usually mild)
Duct destruction present May be present
Table 3. Specific features in liver biopsy differential diagnosis and pathological findings
7. Use of liver biopsy in clinical practice
Here we will discuss some of the most prominent findings of liver biopsy in the following
clinical settings:
a. Viral Hepatitis : Hepatitis B, Hepatitis C.
b. Metabolic diseases: Hemochromatosis, Porphyria, Wilson disease, Alpha 1- anti-trypsin
disease.
c. Autoimmune and cholestatic diseases: Auto-Immune Hepatitis, Primary Biliary Cirrho‐
sis (PBC), Primary Sclerosing Cholangitis (PSC), Overlap Syndrome.
d. Alcoholic liver disease
e. Non-alcoholic Fatty Liver Diseases and Non-Alcoholic Steato-Hepatitis (NAFLD and
NASH). Liver steatosis.
f. Drug-Induced Liver Injury (DILI).
g. Infections and pyrexia of unknown origin.
h. Cirrhosis. Fibrosis progression.
i. Hepatocellular Carcinoma (HCC) and other benign or malignant focal lesions. The role
of the fine neddle aspiration biopsy (FNAB) and other imaging diagnostic tools.
j. New evolving fields for liver biopsy: Liver transplantation and living donors. Bone
marrow transplantation. Morbid obesity
7.1. Chronic viral hepatitis C and B
In the past the majority of liver biopsies were performed in chronic hepatitis C patients.
However, recently this has changed, due to a better understanding of the etiology, patho‐
genesis, the natural history of the disease and available therapies.
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As the ability to treat hepatitis C effectively improves, the value of information gained from a
liver biopsy decreases. The most effective therapy currently available, a combination of pegy‐
lated interferon α and ribavirin, can induce sustained viral clearance, implying a definitive
cure and improved long term prognosis. This occurs, after anti-viral treatment in up to 80% of
patients infected with genotypes 2 and 3. In patients with genotype 1 receiving recently ap‐
proved telaprevir and boceprevir, triple therapy constituents, an average of 70-75% can ach‐
ieve sustained viral clearance. Due to the high percentage of positive response in persons with
genotypes 2 and 3, the need for a liver biopsy in such cases has been questioned.
The terminology used to assess the appearance of liver biopsies with chronic viral hepatitis
has also evolved.
The first classification of chronic hepatitis based on histological criteria was published in
1968. At that time, only three diseases causing chronic hepatitis could be diagnosed, hepati‐
tis B, non A-non B (hepatitis C, since 1989) and autoimmune hepatitis. This classification
which also had prognostic implications only had two categories, namely "chronic persistent
hepatitis" and "chronic active hepatitis". Three years later, the term chronic lobular hepatitis
was added to represent findings similar to those observed in acute hepatitis.
During the 1990s, there were great changes in the understanding of chronic viral hepatitis
by pathologists and hepatologists. The new concepts recognized that the traditional catego‐
rization of pathologic changes (chronic persistent hepatitis, chronic lobular hepatitis, and
chronic active hepatitis) was inadequate for assessing histological changes during clinical
trials. Pathologic processes were separated rather than considered as part of a continuum of
pathologic changes that occur in chronic hepatitis C. Pathologists introduced the idea of
staging for fibrosis and grading for the inflammatory component to the pathological evalua‐
tion of chronic hepatitis C.
7.1.1. Grading and staging of chronic hepatitis C Scoring Systems (Table 4) [16-20]
Grading is the assessment of the activity of a disease, which may increase and decrease as a
disease flares and subsides, or may remain static throughout the disease.
Grade and stage evaluation is a standard part of the pathologic assessment of liver biopsies in
chronic hepatitis. Pathological staging has focused on the assessment of fibrosis as the best
surrogate marker of the disease process. Staging divides the fibrotic continuum into discrete
categories and all of the existing staging systems have cirrhosis as their highest stage. Several
systems exist for grading and staging of chronic hepatitis and all have been used effectively to
assess changes in pathology following therapeutic intervention. These systems include the
methods of Scheuer, Desmet, Batts and Ludwig,and the METAVIR system used to score indi‐
vidual features of inflammation and fibrosis semi-quantitatively in clinical studies [14-20].
Steatosis and Steatohepatitis in chronic hepatitis C Steatosis in hepatitis C is mainly macro‐
vesicular and a common finding in genotype 3 [21] it is also related to a high body mass in‐
dex and older age. More recently, steatosis has been recognized as a feature worthy of
study, from an etiologic standpoint and especially in terms of its clinical significance. Esti‐
mation of the degree of steatosis has been hampered by the lack of standard definitions and
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breakpoints between grades. Although the intrinsic mechanism and involved factors for ac‐
celerated fibrosis are unclear, steatosis has been associated with increased inflammation,
hepatocellular apoptosis and the presence of perisinusoidal fibrosis [22].
Utility of biopsy in hepatitis C. Nowadays, the majority of Hepatitis C patients can be man‐
aged without having to undergo a liver biopsy since liver biopsy rarely identifies unsuspect‐
ed etiology and hepatitis C diagnosis relies on blood antibody and HCV RNA
determinations. However, a biopsy allows to identify patients most in need of therapy or to
find clinically unsuspected cirrhosis, which when found it is necessary to screen for varices
and hepatocellular carcinoma.
Moreover clinical and laboratory surrogates for biopsy may be useful in identifying cirrho‐
sis and biopsy is not necessary if clinical, image and analytical data concur. Post-treatment
biopsy is not needed, nevertheless a new liver biopsy, could be performed if new treatments
or clinical trials arrive in order to stratify patients by prognosis.
Fibrosis stage Knodell et al.
1981 [16]
Scheuer, 1991
[17]
METAVIR, 1994
[18]
Batts and
Ludwig, 1995
[19]
Ishak et al. 1995 [20]
0 No Fibrosis No Fibrosis No Fibrosis No Fibrosis No Fibrosis
1 Fibrous portal
expansion
Enlarged fibrotic
portal tracts
Portal fibrosis Fibrous expansion of
some portal areas, with or
without short fibrous
septa
2 Periportal or
portal-portal
septa but intact
architecture
Enlargement of
portal tracts
Periportal
fibrosis
Fibrous expansion of
most portal areas, with or
without short septa
3 Bridging
Fibrosis (portal-
portal or portal-
central linkage
Fibrosis with
architectural
distortion but no
obvious cirrhosis
Septal fibrosis Fibrous expansion of
most portal areas with
occasional portal to
portal bridging
4 Cirrhosis Probable or
definite cirrhosis
Cirrhosis Fibrous expansion of
portal areas with marked
bridging (portal to portal
as well as portal to
central)
5 Marked bridging with
occasional nodules
(incomplete cirrhosis)
6 Cirrhosis probable or
definite
Table 4. Comparison of commonly used scoring systems for fibrosis staging in chronic Hepatitis C
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7.1.2. Natural history
The degree of inflammation, fibrosis stage, and steatosis seen on liver biopsy are key histo‐
logical predictors of progression to cirrhosis. (Table 5) (see page 28).
Based on retrospective data, it has been shown that most patients with moderate inflamma‐
tion on initial liver biopsy developed cirrhosis after 20 years, and nearly all patients with se‐
vere inflammation or bridging fibrosis developed cirrhosis in 10 years. Patients with mild
inflammation and/or minimal fibrosis have a low risk of progression to cirrhosis. Hepatic
steatosis is also an emerging risk factor for fibrosis progression in hepatitis C [22]. Clinical
information may help to refine prognosis, but cannot substitute the valuable information ob‐
tained from a liver biopsy. Poynard’s group showed three clinical factors which are inde‐
pendently associated with faster progression of fibrosis: male, aged over 40 at the time of
infection, and having a daily alcohol consumption of 50 grams or more [23]. Other factors
predicting progression to cirrhosis include immunosuppression and co-infection with hepa‐
titis B or HIV [24].
Utility of biopsy in hepatitis B Liver biopsy is not mandatory but may show moderate or
severe inflammation which is why before starting antivirals, usually for a long period, our
protocol is to perform a liver biopsy and to individualize the therapeutic decision [25]. It has
been proved that long-term therapy may improve histology but the role of serial liver biop‐
sies has yet to be established outside of clinical trials. Fibroscan has yet to be validated for
patients with chronic hepatitis B but research on this is ongoing [26].
It is important to identify cirrhosis to indicate anti-hepatitis B therapy and hepatocellular
carcinoma screening is also recommended for all hepatitis B surface antigen-positive
(HBsAg+) patients, cirrhotic or not. New guidelines on anti-HBV treatment say that it is ad‐
visable to treat patients with elevated DNA-HBV and minimally elevated or fluctuating ala‐
nine aminotransferase (ALT), [27, 28].
Features typical of chronic viral hepatitis inflammation, like fibrosis, is considered to be one
of the key characteristics of chronic viral hepatitis. It is a chronic necroinflammatory process
in which hepatocytes are preferentially injured compared with bile ducts. The grade of in‐
flammation is a stratification of the overall necroinflammatory changes into mild, moderate,
and marked categories. Unlike the fibrosis systems, which are based on distinctive architec‐
tural changes that can be highlighted with special stains, assessment of inflammation is
more subjective and hence shows more interobserver variations. Usually varying degrees of
portal and periportal inflammation(with lymphocytes, plasma cells, and macrophages), lo‐
bulillar hepatitis, and fibrosis are to be individually considered and scored.
Interface hepatitis occurs when the inflammatory infiltrate crosses the limiting plate; it is
usually associated with local hepatocyte damage, piecemeal necrosis, and inflammation.
Lobular  inflammation  is  accompanied  by  some  hepatocellular  necrosis  (acidophilic  or
Councilman  bodies).  Chronic  hepatitis  leads  to  progressive  fibrosis  and,  without  treat‐
ment,  to cirrhosis.  The fibrosis begins in portal areas,  extends to periportal areas,  bridg‐
ing  also  other  portal  tracts  and  central  veins.  Histopathological  findings  in  the  liver
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biopsy that  help to  predict  etiology chronic  hepatitis  B may show some of  the changes
described  previously,  as  well  as  a  ground-glass  change  to  the  cell  cytoplasm.  This
change reflects accumulation of hepatitis B surface antigen within the endoplasmic retic‐
ulum of the hepatocytes [29].
Chronic hepatitis C may be associated with prominent lymphoid aggregates within portal
tracts, sometimes including germinal centers and, occasionally, bile duct damage, although
not to the degree seen in line primary biliary disorders. In addition, biopsies may show fo‐
cal, nonzonal macrovesicular steatosis [30].
Patterns of liver cell injury found in liver biopsy and differential diagnosis. Chronic viral
hepatitis have no unique histopathologic features, it is therefore necessary to consider vari‐
ous causes. In addition to viral infection, chronic hepatitis may be autoimmune or drug re‐
lated. Histological features of chronic cholestatic disease, including PBC, primary sclerosing
cholangitis (PSC), autoimmune cholangitis, as well as metabolic diseases including Wilson
disease and α1-antitrypsin deficiency, may overlap with some of the findings with “so
called” chronic hepatitis.
7.2. Metabolic liver diseases
Many rare diseases originate in the liver, either affecting the liver directly or causing extra-
hepatic disease [31]. For example, liver histology is usually normal in primary hyperoxaluria
while the kidneys and other organs may be irreparably damaged; however, cure is only pos‐
sible with a liver transplant. In other inherited disorders, the liver disease may remain
asymptomatic until precipitous acute liver failure develops; the classic example is Wilson
disease. Here we present the diseases most frequently observed in adult patients.
7.2.1. Hematochromatosis: The role of liver biopsy in the diagnosis of hepatic iron overload in the era
of genetic testing [32]
Hemochromatosis is an autosomal recessive disorder that leads to massive deposits of iron
in many organs, including liver, pancreas, heart, joints, and skin. The gene responsible for
hereditary hemochromatosis, HFE, is located on chromosome 6. The two most common mu‐
tations are C282Y (present in up to 80% of cases) and H63D. The defining characteristic of
this disease is the failure to prevent unneeded iron from entering the circulatory pool as a
result of genetic changes compromising the synthesis or activity of hepcidin, the iron hor‐
mone.Hemochromatosis results from the interaction between genetic and acquired factors.
Depending on the underlying mutation, the coinheritance of modifier genes, the presence of
nongenetic hepcidin inhibitors, and other host-related factors, clinical manifestation may
vary from simple biochemical abnormalities to severe multiorgan disease [33]. The indica‐
tion of a liver biopsy in the era of genetic testing is being questioned. But, in our opinion,
liver biopsy continues to play an important role in the diagnosis, prognosis and manage‐
ment of patients with elevated serum ferritin and abnormal liver function test results in gen‐
eral hepatology practice. Genetic tests for HFE mutations (C282Y, H63D) and liver biopsies
are complementary in the workup of these patients.
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Liver biopsy allows a quantitative iron concentration study and the identification of the
grade of hepatic iron overload, localization pattern and associated liver pathology for diag‐
nosis and management of patients [34].
Liver biopsies may be relatively normal or show bridging fibrosis or even micronodular cir‐
rhosis. Untreated, hemochromatosis leads to the development of micronodular cirrhosis.
Prior to the availability of genetic testing, the diagnosis of hemochromatosis was always de‐
termined with liver biopsy and quantitation of tissue iron. With the availability of genetic
testing for the C282Y and/or H63D mutations, liver biopsy is more often reserved for evalu‐
ation of clinical status or complications (i.e. degree of fibrosis, development of hepatocellu‐
lar carcinoma) rather than for primary diagnosis [35]. A biopsy can also help determine if
other disease processes are present, such as hepatitis C or fatty liver disease [36].
We suggest that patients with suspected hemochromatosis undergo genetic testing for the
C282Y and H63D mutations, especially if they have a family history of hemochromatosis,in
order to establish the genotype of the patient and permit genetic counseling. A liver biopsy
may not be necessary in young C282Y homozygotes or in heterozygotes without evidence of
liver disease.
Disorders that have to be considered in the clinical differential diagnosis of hemochromatosis
The list of disorders associated with increased hepatic iron is long. The majority of patients
with hepatic iron accumulation from any cause do not have hepatic iron concentration (HIC)
that is above the upper limit of normal (approximately 1100 mg/µg dry liver weight). Fur‐
thermore the pattern of distribution of the iron in the liver may be of some help in establish‐
ing the diagnosis [37]:
• predominantly hepatocellular distribution of iron leads to a diagnosis of genetic hemo‐
chromatosis, alcoholic liver disease and/or porphyria cutanea tarda.
• predominant presence of iron in Kupffer cells, may be the result of multiple transfusions
and/or hemolytic anemias.
• a mixed distribution of iron may be a sign of megaloblastic anemia or anemia secondary
to chronic infection.
7.2.2. Porphyria Cutanea Tarda (PCT)
It is the most common form of porphyria across the world. PCT is usually an acquired liver
disease caused by exogenous factors, such as excess alcohol intake, iron overload, chronic
hepatitis C and oestrogen therapy.
The pathogenesis of PCT is varied; it may be hereditary or acquired, leading to hepatic iron
loading and to an increase of oxidative stress. Iron loading is usually only mild or moderate
in degree. However, in patients with excessive alcohol intake and/or chronic hepatitis C in‐
fection, hepcidin production by hepatocytes decreases. This decrease is responsible for in‐
creased iron absorption from the gut. The important role that PCT often plays in the
hepatitis C virus setting has recently been emphasized [38].
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7.2.3. The role of liver biopsy in determining the diagnosis of Wilson disease
Wilson disease is an autosomal recessive disorder of copper metabolism, characterized by
excessive accumulation of copper in the liver and other organs. Genetic evaluation is diffi‐
cult because most patients are compound heterozygotes. For patients with Wilson disease
the norm is to perform a liver biopsy with a quantitative copper testing of the liver; levels
are typically greater than 250 mg/g dry weight liver (normal level, 38 mg/g) [39].When the
diagnosis of Wilson disease is considered prior to liver biopsy other tests are undertaken. -
Serum ceruloplasmin (less than 20 mg/dL in patients with Wilson disease; normal levels, 23
to 50 mg/dL). - 24-hour urinary copper (greater than 100 mg/dL; normal, less than 30 mg/
dL). -Kayser-Flescher ring has to be studied by ophthalmologic testing. The liver biopsy in
this disease can present differently, depending on the patient’s age. In children and young
adolescents, the most common finding may be fatty change. In older adolescents and young
adults, a liver biopsy may show chronic hepatitis with piecemeal necrosis. Adults tend to
show cirrhosis, and Mallory bodies*. In adolescents or adults, confluent necrosis may lead to
a severe hepatic failure that may require an urgent liver transplant [40].
7.2.4. Alfa1 -antitrypsin (A1-AT) deficiency on liver biopsy
A1-AT is the major circulating inhibitor of serine proteases (Pi). Its primary target is the po‐
tent elastase found in polymorphonuclear cells (PMNs). It is a glycoprotein synthesized in
the liver. Many of the Pi variants are associated with fairly normal serum concentrations and
function and thus are of little clinical significance. However, a few, result in low circulating
levels of α1-AT (i.e., PiZZ) and are of pathologic significance. Liver biopsies from affected
patients demonstrate classic PAS-positive, diastase-resistant globules within periportal hep‐
atocytes. Portal fibrosis and chronic hepatitis may also be present. Liver cell dysplasia may
be seen, and patients older than 50, especially men, are at risk of developing hepatocellular
carcinoma. The presence of PAS-positive, diastase-resistant globules is not always diagnos‐
tic for A1-AT deficiency because various inflammatory conditions may be associated with
overproduction of the enzyme, as is the case in cardiac congestion or hypoxia. For this rea‐
son clinical correlation is required [41].
7.3. Autoimmune Hepatitis (AIH)
Autoimmune hepatitis (AIH) is an inflammatory condition of the liver that can affect pa‐
tients of all ages, sexes, and races [42].
Timely diagnosis and immunosuppressive therapy may control disease activity in almost all
affected patients and various case series have reported near normal or normal life expectan‐
cy in patients diagnosed and treated adequately [43]. Untreated AIH, however, has 5-year
mortality above 50%.
It was first described as a form of chronic hepatitis in young women, showing jaundice, ele‐
vated gammaglobulins and amenorrhea, which eventually leads to cirrhosis. There is not a
single test to diagnose AIH but a set of diagnostic criteria has been suggested in order to
classify patients as having probable or definite AIH depending on a score.
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Clinical appearance ranges from an absence of symptoms to a severe fulminant presenta‐
tion. It is usually clinically associated with other autoimmune diseases such as rheumatoid
arthritis, ulcerative colitis, autoimmune thyroiditis, or diabetes mellitus. A family history
has been reported [44].
A liver biopsy should be obtained at first diagnosis before therapy for grading, staging and
confirmation of the diagnosis. Histological appearance is not characteristic, although typical
features such as periportal hepatitis with lymphocytic infiltrates, plasma cells and piecemeal
necrosis, with more advanced disease bridging necrosis, are frequent. Variable degrees of
portal fibrosis are present [45]. In non treated patients or in non-responsive to corticosteroid
therapy cirrhosis eventually occurs.
Differential diagnosis which has been revisited recently by the International Autoimmune
Hepatitis Group comprises: chronic hepatitis not caused by other etiologies (viral, drug-in‐
duced), acute hepatitis alone or acute hepatitis superimposed on underlying chronic liver
disease and autoimmune diseases with associated duct damage and duct loss [47].
Early diagnosis may be difficult because the clinical picture is heterogeneous and the liver
histology sometimes shows atypical features.
A simple  and accurate  diagnostic  scoring system for  AIH has  been established but  not
totally  validated  yet.  In  1993,  the  International  Autoimmune  Hepatitis  Group  (IAIHG)
proposed  specific  diagnostic  criteria,  which  were  revised  in  1999.  These  criteria  were
made by expert consensus and introduced to allow comparison of studies from different
centers  [46].  Some  of  the  items  were  of  questionable  value  which  is  why  in  2008  the
IAIHG published a new simplified scoring system for wider applicability in routine clini‐
cal practice, based on the data of patients with well-established diagnoses and validated
in another group of  patients  [47].The new score includes autoantibodies,  immunoglobu‐
lin G, histology, and exclusion of viral hepatitis, allowing a reliable diagnosis of AIH ap‐
plying simple scores.
7.3.1. Primary Biliary Cirrhosis (PBC)
PBC is a chronic progressive cholestatic liver disease that occurs in middle-aged patients,
usually women, and is often associated with other autoimmune diseases. Patients may
present with jaundice and pruritus in advanced cases. Laboratory testing reveals serum an‐
ti–mitochondrial antibody (AMA) as well as increased alkaline phosphatase, bilirubin, and
γ-glutamyl transpeptidase [48]. The histological staging of PBC considers the degree of bile
duct damage and fibrosis [49].
- Stage 1 early disease is characterized by damage to septal and larger interlobular bile
ducts, reflected by biliary epithelial damage with infiltration of the duct by lymphocytes,
plasma cells, eosinophils, and rare polymorphs. The inflammatory infiltrate confined within
the portal tract, may include granulomas and lymphoid follicles (florid duct lesion).
- Stage 2 the inflammatory process extends beyond the portal tract, and changes of interface
hepatitis (piecemeal necrosis) may be seen. Bile ducts begin to disappear and proliferation of
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bile ductules (cholangioles) may also be present along the edges of the portal tracts. These
changes are associated with features of chronic cholestasis, including feathery degeneration
within the cytoplasm of hepatocytes, accumulation of bile pigment, periportal accumulation
of copper (not generalized as in Wilson disease), and, occasionally, Mallory bodies*.
- Stage 3 is associated with increasing fibrosis and bridging between portal areas, with de‐
creased amounts of inflammation.
- Stage 4 represents biliary cirrhosis, usually micronodular. In the past the diagnosis was
done in very advanced disease, biliary cirrhosis, hence its name.
7.3.2. Primary Sclerosing Cholangitis (PSC)
Primary sclerosing cholangitis (PSC) is a disease with a variable clinical course, with obliter‐
ation of the biliary tree that leads to biliary cirrhosis and its complications such as portal hy‐
pertension and liver failure. The term “primary” is used to distinguish this condition from
the bile duct strictures that are secondary to bile duct injury, cholelithiasis or ischaemia [50].
Patients  may present  with increased alkaline phosphatase and positive perinuclear  anti‐
neutrophil cytoplasmic antibodies (pANCAs). In this disease, liver biopsy does not have
a crucial  role  in  the  diagnosis.  Ultrasound is  used for  the  initial  investigation and may
show  bile  duct  dilatation  and  liver  and  splenic  changes;  however,  it  is  unspecific  for
PSC. [51,52]. The classic lesion of PSC in the histological study is onionskin or concentric
periductular fibrosis, with damage to the ductal epithelium, but it  is rarely seen on per‐
cutaneous biopsy. The most common findings on a biopsy in early-stage disease are non‐
specific [46], fibrosis with inflammation of portal tracts and paucity of normal bile ducts.
In addition, in patients with extrahepatic obstruction, proliferation and dilatation of inter‐
lobular ducts and an increased number of periportal PMNs can be observed. Endoscopic
retrograde cholangiopancreatography (ERCP) is  the next choice test  for diagnosis,  but it
is  invasive,  for  this  reason  its  role  is  under  debate  [53].  Transhepatic  cholangiography
can be used if  ERCP is  unsuccessful,  but again is  invasive.  Non-invasive alternatives to
ERCP are:  magnetic  resonance cholangiopancreatography (MRCP),  which is  increasingly
used  and  is  useful  for  excluding  other  disease  and  evaluating  the  biliary  system  [54].
Transient elastography (FibroScan®) has potential as a non-invasive method for detection
of cirrhosis in patients with more advanced liver disease [55].
PSC shares many clinical biochemical and pathologic features with primary biliary cirrhosis,
although PSC, can affect both intrahepatic and extrahepatic ducts. PSC is strongly associated
with inflammatory bowel disease, particularly ulcerative colitis. Due to its major morbidity
and mortality the diagnosis has to be confirmed. At the time of diagnosis, PSC typically in‐
volves both intra and extrahepatic bile ducts in the majority of cases. The most dismal se‐
quel of PSC is the development of colangio carcinoma (CC) in 14% of patients (which may
not be demonstrable radiographically with the usual diagnostic methods) [56].
A wide spectrum of disease severity exists, ranging from patients who present with ad‐
vanced liver disease requiring liver transplantation within a short time to those who remain
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asymptomatic for decades. The natural course of PSC is determined by interindividual vari‐
ability, the rate of progression and the development of CC, which can occur at any time.
The differential diagnosis has to be established among : autoimmune hepatitis, overlap syn‐
dromes, infectious hepatitis, other bile duct diseases presenting as acute or chronic cholangi‐
tis, and biliary strictures, cholangiocarcinoma, gallstones, hepatomegaly and primary biliary
cirrhosis.
Liver biopsy in PSC is only needed to diagnose small-duct PSC or to exclude other diseases
that may be associated with PSC or with similar features and confounding aspects. Liver bi‐
opsy also may be useful for staging the disease. However, serial liver biopsy in monitoring
the disease is not indicated [57].
Recently some authors have developed the Mayo clinic risk score, a multivariate statistical
survival model, on the basis of the long-term course of the disease in 486 PSC patients seen
at three centers in United States. In this score, the need for liver biopsy has been eliminated.
This scoring system has its advantages; it is non-invasive and was found to be well correlat‐
ed to actual survival. It also performs better than the Child-Pugh classification for cirrhosis,
which does not predict survival with PSC [58].
7.3.3. Autoimmune Hepatitis (AIH) with overlap variants
Overlap syndromes of AIH are not uncommon but are not well defined. Histology, clinical
and serological indicators imply more than one liver disease at the same time.
The diagnosis of an overlap syndrome relies on the biochemical profile, either cholestatic or
hepatitic in addition to the auto-antibodies pattern and elevated gamma globulins. The his‐
topathology can show portal inflammation with or without involvement of bile ducts [59].
In adult patients with an overlap of PBC and AIH, which is the the most common, antinu‐
clear as well as antimitochondrial antibodies are present. Chronic hepatitis C may trigger
autoimmune activation, with concomitant positive autoimmune antibodies. AIH may be as‐
sociated with Ig G4 autoimmune cholangitis (IAC). In contrast to PSC, IAC-IgG4, has no as‐
sociated intestinal bowel disease and pancreatitis [60].
The value of a biopsy in liver diseases such as PSC or suspected metastatic disease, which is
characterized by a zonal affection of the liver has to be dealt with individually and complet‐
ed with other imaging techniques.
Liver biopsy is advisable if diagnostic tests show abnormal liver function results which may
be indicative of many etiologies e.g. nonalcoholic steatohepatitis with strongly elevated anti‐
nuclear antibodies and abnormal iron studies, or co-infection with HIV and hepatitis C in a
patient with abnormal liver function tests taking hepatotoxic drugs etc.
7.4. Alcohol: Fibrous progression related to alcohol injury
Many patients  with  ethanol  injury show initial  scarring around central  veins  with  deli‐
cate fibrosis along the sinusoids [61]. Eventually, bridging fibrosis connects central veins
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and  portal  tracts.  When  cirrhosis  is  fully  developed,  most  of  the  native  central  veins
have  been  obliterated.  Alcoholic  cirrhosis  is  micronodular  and the  scarring  is  relatively
uniform throughout the liver. With complete alcohol abstinence, the nodules can regener‐
ate to a larger size, but the central veins are decreased in number and the nodules may
lack some portal tracts [62].
7.5. Non-Alcoholic Fatty Liver Disease, (NAFLD) and Non-Alcoholic Steatohepatitis,
(NASH)
The histological appearance in these disorders may be very similar to the injury related to
alcohol. In non-alcoholic steatohepatitis, the liver exhibits fat and perivenular sinusoidal col‐
lagen deposition and may be indistinguishable from alcoholic perivenular fibrosis on histo‐
logical grounds alone. Clinical correlations are basic for its diagnosis [63].
Sometimes a biopsy shows a pattern which looks like alcoholic hepatitis, but the patient de‐
nies alcohol use. A differential diagnosis for alcoholic hepatitis has to be done, and non-alco‐
holic fatty liver disease, (NALDF) and non-alcoholic steatohepatitis, (NASH) should be
considered [63].
For many decades, typical “alcoholic hepatitis” was often diagnosed with liver biopsy, and
in some patients’ medical records were completed with somewhat judgmental comments
about their persistent denial of alcohol intake. Now, there are other known causes for Mallo‐
ry bodies (*) and steatosis found in liver biopsies which, in the past, were classified as alco‐
hol related liver injury. In retrospect, we now know that many patients with “alcoholic
hepatitis” were treated unfairly [64].
It is clear that similar patterns of injury can be seen in non-alcoholics, especially in the set‐
ting of diabetes and obesity, referred to as nonalcoholic steatohepatitis (NASH) or nonal‐
coholic  fatty  liver  disease  (NAFLD).  This  represents  a  significant  form  of  chronic  liver
disease in both adults and children, with a spectrum ranging from indolent to end-stage
liver disease. It may be an underlying cause of cryptogenic cirrhosis and has been report‐
ed to recur after a liver transplant. Other conditions associated with NASH include acute
starvation,  accelerated weight  loss,  intestinal  bypass,  disorders  of  lipid metabolism,  and
various  drugs.  Careful  clinicopathologic  correlation  is  required  to  determine  the  cause.
Liver biopsy evaluation allows us to establish the degree of steatosis,  inflammation, and
fibrosis stage [65].
Liver steatosis
The diagnosis of liver steatosis has several implications in chronic liver diseases.
• Liver steatosis is associated with liver fibrosis progression and a decreased rate of sus‐
tained viral response in chronic hepatitis C.
• Donor liver macrovesicular steatosis is independently associated with graft failure at one
year after liver transplantation.
• After major hepatic resection, liver steatosis induces an increased risk of post-operative
complications and elevated risk of death.
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• Finally, liver steatosis is the main lesion observed in non-alcoholic fatty liver disease
(NAFLD) which, as a consequence of the worldwide burden of visceral obesity, is now an
important cause of chronic liver disease in western countries.
At present, the histological examination of a liver biopsy continues to be the reference for
evaluating liver steatosis despite its  limitations.  The procedure is  invasive and impaired
by sampling bias, which results in imperfect reproducibility and only allows for a semi-
quantitative grading of steatosis [66]. The non-invasive diagnosis of liver steatosis is done
by imaging techniques and blood tests,  but diagnostic  accuracy remains to be validated
and their use in clinical practice has yet to be recommended. Ultrasonography is consid‐
ered the imaging technique of choice for steatosis screening, but its sensitivity in detecting
fatty liver is only 60–94% and is operator dependent. Other techniques, such as computed
tomography,  proton  magnetic  resonance  spectroscopy  and  magnetic  resonance  imaging
offer high accuracy for quantification of liver fat but have low availability, high cost and
lack standardization [67].
The diagnosis of hepatic steatosis and steatohepatitis or non-alcoholic steatohepatitis
(NASH) is not yet possible without liver biopsy. Therapeutic targets of drug development
are in early stages. As regards the study of factors most likely associated with disease pro‐
gression, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has
sponsored the NASH Clinical Research Network (CRN) who has developed a histological
scoring system, which is used for clinical trials for NASH [68].
The histological lesions for the diagnosis of NASH are: zone 3 macrosteatosis, hepatocyte
ballooning and mixed lobular inflammation. Other findings that are common include mild-
moderate portal inflammation, acidophil bodies, glycogenated nuclei, lipogranulomas and
perisinusoidal fibrosis. In addition, the following may be present: Mallory’s hyaline (*) in
hepatocytes, megamitochondria and mild siderosis.
(*) Mallory bodies or Mallory’s hyaline are irregular, rope-like eosinophilic intracytoplasmic
strings that represent aggregates of cytokeratin filaments. The cytokeratins form a filamen‐
tous support network within the hepatocytes. Cellular damage is due, for example, to etanol
producing hepatocyte ballooning degeneration, which can cause the keratins to misfold and
aggregate. Mallory bodies may be found in alcoholic, nonalcoholic steatohepatitis, and Wil‐
son disease, cholestatic conditions such as primary biliary cirrhosis (PBC) and with certain
drugs, such as amiodarone. Although the fat and neutrophils can resolve relatively quickly
after alcohol abstinence, hyaline can take up to 6 weeks to disappear [69].
The histological severity of NAFLD is determined by the Non-alcoholic fatty liver disease
Activity Score (NAS) and the Fibrosis Score, developed and validated by the CRN [68]. This
scoring system is very useful for assessing change in clinical trials but it is not meant to re‐
place a full interpretation of histological findings by a pathologist [70].
Some investigators  have observed that  there  is  significant  sampling variability  and that
the histological lesions of NASH are unevenly distributed throughout the liver parenchy‐
ma and can lead to substantial misdiagnosis and staging inaccuracies. For example, Rat‐
ziu et al.  reported that on 51 patients with NAFLD who underwent paired biopsies, the
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discordance rate for steatosis would have been missed in 24% of cases if only one biopsy
had  been  done  and  a  difference  of  one  stage  of  fibrosis  or  more  was  seen  in  41%  of
paired biopsies [71].
7.6. Liver injury caused by drugs
Drug and toxin induced liver injury is a common cause for abnormal liver tests in humans
[72]. Liver injury related to drugs can be subdivided into intrinsic and idiosyncratic injury.
Intrinsic injury is produced through direct or indirect mechanisms and idiosyncratic injury
may be mediated by hypersensitivity or by metabolic toxic metabolites [73].
Drug induced liver cell injuries have different morphological patterns such as, hepatocellu‐
lar injury, cholestatic injury, bile duct injury, vascular injury, portal fibrosis, neoplasia or
miscellaneous (pigments and inclusions).
The  list  of  implicated  products  is  very  long  and  in  some  cases  mixed  lesions  can  be
found. Drug “signature” is a well-known concept which implies that the drugs responsi‐
ble  for  the  injury can be  identified from the  different  lesions  it  causes  to  the  liver.  For
example,  diclofenac  and  minocyline  produce  a  chronic  hepatitis  pattern,  steatohepatitis
can be induced by amiodarone and tamoxifen,  vascular toxicity may be associated with
azathioprine etc. [74].
Histological changes that suggest drug- or toxin-related liver injury are atypical therefore, in
some cases, depending on the findings, it is worth the pathologist asking the clinician specif‐
ic questions in order to do a differential diagnosis and to identify the drug [75]:
Is the patient’s blood analysis compatible with hepatitis? Has viral injury been excluded?
• What are the patient’s toxic exposures at work, home, or play?
• Has every drug been sought and disclosed?
• Granulomas (**) may also be part of the inflammatory reaction in drug injury [76].
If  granulomas  have  been  found,  have  other  causes  of  granulomas  been  excluded?  (see
below) [77]
If significant fatty change is found is there any possibility that it could be related to toxic
ethanol injury?
If an abundance of eosinophils is observed in a liver biopsy, a hypersensitivity reaction is
suspected which may resemble viral hepatitis. Eosinophils may also be present nonspecifi‐
cally in viral hepatitis, in connective tissue disorders, and in some neoplasms (usually in
Hodgkin’s disease infiltrates). However, when eosinophils are a striking feature, it is advisa‐
ble that the clinician search for a drug, a toxin, or even a nutritional supplement (“natural
medicines”).
If numerous liver cell mitotic figures show up in the liver biopsy, this may suggest that a
short episode of drug exposure is to blame.
Rethinking the Role of Liver Biopsy in the Era of Personalized Medicine
http://dx.doi.org/10.5772/53120
51
7.6.1. Drug Induced Liver Injury (DILI) examples
The  American  Association  of  Reumatology  has  provided  guidelines  for  monitoring  pa‐
tients receiving Methotrexate therapy as there is a known relation between this treatment
and hepatotoxicity [78].
A few years ago methotrexate was used for treating reumathoid arthritis. Now patients with
psoriasis are also treated with this drug, albeit at a lower dose. Many potentially hepatotoxic
medications, used in such cases are worth investigating [78].
Amoxi-clavulanic  acid  is  one  of  the  examples  of  a  broadly  used  antibiotic  which  has
been  implicated  in  liver  toxicity.  Typically  the  patient  with  this  toxicity  presents  with
jaundice.  After  excluding  other  causes,  such  as  viral  hepatitis,  autoimmunity,  or  other
etiologies,  and  in  presence  of  a  normal  biliary  tree,  a  liver  biopsy  is  recommended,
which  may  show  a  cholestatic  hepatitis  pattern.  After  discontinuation  of  the  drug  the
evolution is usually favourable [79].
7.6.2. Granulomas in liver biopsies
Granuloma is defined as an aggregate of histiocytes and can only be diagnosed through his‐
topathological examination.
Causes of granulomas in the liver: most systemic granulomatous diseases involve the liver
to some extent; tuberculosis and sarcoidosis are the most common causes [80]. Other infec‐
tious agents include bacteria (brucellosis, nocardiosis, tularemia, Q fever [Coxiella burnetii],
spirochetes), various fungi, protozoa, and viruses (cytomegalovirus, Epstein-Barr virus).
Noninfectious causes in addition to sarcoidosis include PBC, drug reaction, extrahepatic in‐
flammatory disease, such as chronic inflammatory bowel disease, rheumatoid arthritis), neo‐
plasms (Hodgkin disease) and foreign substances (talc, mineral oil) .
7.6.3. Can negative stains for fungi and acid-fast bacilli exclude infection in patients with fever of
unknown origin?
Definitely not. Cultures for these organisms are more sensitive than special histological
stains. If infection is a possibility, a core of liver should be submitted with sterile precautions
and without fixative to the microbiology laboratory. In addition, tissue in formalin should
be sent to the pathology laboratory for microscopic sections. A tissue sample may also be
sent for molecular analysis to determine whether an infectious agent is present, depending
on the possibilities [82, 83].
7.6.4. Different types of granulomas useful in determining specific diagnosis
• Epithelioid granulomas are nodular aggregates of plump macrophages, often associated
with multinucleated giant cells, lymphocytes, and plasma cells. They are typically seen in
sarcoidosis. The presence of central caseating necrosis suggests tuberculosis.
• Fibrin-ring granulomas are formed by a fibrin band encircling a lipid droplet, with associ‐
ated inflammation. They were first described with Q fever but may also be seen after in‐
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fection with cytomegalovirus or Epstein-Barr virus as well as with drug (allopurinol)
toxicity and in association with systemic lupus erythematosus.
• Lipogranulomas are composed of lipid deposits and vacuolated macrophages. They are
formed in the presence of exogenous or endogenous fat accumulation.
• Microgranulomas may be a nonspecific finding, they are usually subtle and composed of
small, round clusters of plump Kupffer cells.
There are many causes of hepatic granulomas, including local irritants, infections, infesta‐
tions and hypersensitivity to drugs. The constituents of these lesions, depending on the eti‐
ology and inflammatory cytokines produced include large epithelioid cells, multinucleated
giant cells, varied numbers of mononuclear cells and eosinophils. The causes vary in fre‐
quency from one country to another. Although the etiology may be determined from the
histological features, from special stains for micro-organisms, from culture of part of the bi‐
opsy specimen or polymerase chain reaction of the paraffin-embedded specimen, or from
clinical and serological data, the cause of hepatic granulomas remains unknown in one third
of cases. It is likely that approximately one third of granulomatous liver reactions are caused
by drugs, including allopurinol, carbamazepine, procainamide, diphenylhydantoin, quini‐
dine, isoniazid, and sulphanilamide.
7.7. The role of liver biopsy in infections and pyrexia of unknown origin
Although the usefulness of liver biopsy in the diagnosis of fever of unknown origin is still
controversial, a review of the literature shows that liver biopsy can be effective in confirm‐
ing histopathological diagnosis and microbiological analysis [83].
Based on the findings of a liver biopsy evaluating Fever of Unknown Origin (FUO), we can
conclude that abnormal liver biopsy is helpful in determining the cause of the FUO. The
most common cause of fever was of an infectious origin. Other causes were neoplastic disor‐
ders or inflammatory [87].
Liver biopsy was performed after routine studies were negative. Therefore results such as
histoplasmosis and tuberculosis indicate that, despite advances in diagnostic technology,
liver biopsy continues to be useful in the diagnosis of FUO. In endemic areas, histoplasmosis
and tuberculosis should be considered in the differential diagnosis of FUO [85].
7.8. Cirrhosis
Cirrhosis is pathologically defined as a diffuse process in which the normal anatomical lo‐
bules are replaced by architecturally abnormal nodules separated by fibrous tissue. There‐
fore, focal scarring, even if significant and associated with nodules, is not cirrhosis because
the process is not diffuse [86]. In the past the description of a liver as “cirrhotic” implied an
ominous prognosis in a patient with liver disease. In chronic hepatitis, the most important
goal is to delay or to stop the development of cirrhosis. Nowadays, treatments to prevent its
progression are available. At present there are many known stages as opposed to before
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when there only one was considered, G Garcia-Tsao in the article “In search of a pathophy‐
siological classification of cirrhosis.” [86].
7.8.1. Fibrosis progression
One of the most crucial developments is the reformulation of the concept of cirrhosis from a
static to a dynamic process. This concept is likely to be even better defined in the future.
As  fibrotic  scars  advance  and  extend  the  normal  architecture  changes  and  nodules  are
formed [88]. Moreover, the angiogenic process that naturally accompanies scar formation
permits the creation of abnormal channels between central hepatic veins and portal ves‐
sels,  resulting  in  the  shunting  of  blood  around  the  regenerating  parenchyma.  Normal
vascular structures, along with sinusoidal channels, may be obliterated, leading to portal
hypertension.  Some authors  describe cirrhosis  as  a  vascular  disease  [89].  Clinical  conse‐
quences  of  cirrhosis  result  from  the  decreased  ability  of  the  parenchyma  to  synthesize
clotting  factors  and other  substances  combined with  the  complications  related to  portal
hypertension [90].
Knowledge on the level of fibrotic progression between normal histology to cirrhosis has
considerable prognostic weight. Patients with bridging fibrosis on biopsy are much closer to
end-stage liver disease than those with minimal or no fibrosis. Fibrosis is not an autono‐
mous feature, but rather a tissue progressive lesion resulting from other pathologic mecha‐
nisms such as inflammatory, degenerative or dystrophic processes [91].
The first transition in this process occurs between the normal, non-fibrotic state and the ex‐
pansion of the portal area by fibrosis, to the extension of short, incomplete septations
around the portal area, change that gives to the portal areas an irregular stellate shape.
In the next transition, development of bridges between vascular structures, portal-portal
bridging fibrosis and portal-central bridging, occur. Gradually, more and more bridges are
formed, accompanied by distortion of the architecture due to hepatocellular regeneration
and contraction of fibrotic scars. When these changes diffusely involve the biopsy, it is clas‐
sified as cirrhosis [92].
Progressive fibrosis leads to cirrhosis and it is now known that cirrhosis can be reversible.
There was a lot of controversy surrounding this issue a few years ago [93]. For patients in a
precirrhotic stage of fibrosis, liver biopsy remains the gold standard of assessment. Prior to
1995, there was no published system which subdivided advanced stages of cirrhosis. Only
the Ishak modification of the Histologic Activity Index (HAI) subdivided cirrhosis into three
categories [94].
Nowadays, since Garcia-Tsao et al.reported compensated and decompensated phases in the
clinical evolution of liver cirrhosis, many prophylactic measures and controls have been im‐
plemented in order to improve survival and quality of life [87]. Cirrhosis is usually clinically
evident. Once the pathologic stage of cirrhosis has been reached, clinical scales such as the
Child-Pugh score have to be used because they represent the prognosis and the staging of
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the liver disease better [95]. The present debate questioning the need for liver biopsy versus
non invasive tests will be discussed below.
7.8.2. A needle biopsy specimen does not always permit the diagnosis of cirrhosis
Micronodular cirrhosis (nodules of 3 mm or less), which may develop as a result of ethanol
injury, biliary tract disease, or hemochromatosis, is usually uniform throughout the liver,
and nodules may be identified on a needle specimen. However, macronodular cirrhosis
(nodules greater than 3 mm), due most commonly to chronic viral hepatitis, constitutes a
less uniform pattern [96].
7.9. Hepatocellular Carcinoma (HCC) and other benign or malignant focal lesions: The
role of Fine Needle Aspiration Biopsy (FNAB) [97]
Indications of liver biopsy with regards to diffused or local lesions
Liver biopsy is useful for diagnosis of a diffused disease and guided liver biopsy remains
essential for the diagnosis of localized lesions.
7.9.1. Fine needle aspiration biopsy (FNAB)
This technique has a crucial role in the evaluation of focal liver lesions or localized lesions.
Liver tumors appear as nodular or localized lesions which can be malignant or non-malig‐
nant and can be either primary from the liver or metastasic. If clinical, biochemical and radi‐
ologic findings are inconclusive, some phases of the diagnostic process may require a liver
biopsy in order to establish the diagnosis and their staging and management [99].
Malignant lesions. Hepatocellular carcinoma (HCC), the most frequent malignant liver
cancer, is usually discovered during screening programs in cirrhotic patients. Regarding
treatment, the only curative option is surgery, both limited hepatectomy of the tumor or liv‐
er transplant in very select cases [100].
In liver lesions with typically recognized features of HCC, defined by using advanced radio‐
logical methods, liver biopsy has no place. However, a liver biopsy will be performed in pa‐
tients with atypical liver tumors suggestive of a possible colangiocarcinoma. These cases
require another form of therapy and the prognosis is worse [99].
Besides, when surgery is indicated in a patient with suspected liver cirrhosis, a liver biopsy
has to be performed in the non-neoplasic liver. Pathological diagnosis may help to asses the
functional capacity, specific prognosis and whether surgery could be performed.
Metastasis of the liver with an unknown primary tumor should be biopsied to obtain infor‐
mation of the primary tumor in order to determine therapy.
Concern has been expressed about the risk of spreading malignant cells via the needle tract,
but this rarely occurs when using needles with a diameter of less than 1.3 mm, which also
minimizes the risk of bleeding. The procedure is simple, safe and painless [101].
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7.9.2. Non-malignant lesions
In cases of Hemangioma or Focal Nodular Hyperplasia (FNH), diagnosed and confirmed by
radiology, biopsy is usually not necessary.
FNH and hepatic adenoma are benign tumors and are less frequently observed than HCC.
Their diagnosis is done using imaging techniques (ultrasound or helicoidal scanner). How‐
ever, differential diagnosis is necessary because, although FNH only requires radiological
follow-up, in some cases, higher risk circumstances have been recognized and surgery is
recommended [102].
7.9.3. Most prevalent mass lesions [102, 103]
• Benign: cysts, hemangioma, adenoma, liver abscess (amebic or pyogenic), focal nodular
hyperplasia, fatty infiltration, rare primary liver neoplasms.
• Malignant: hepatocellular carcinoma, cholangiocarcinoma, metastatic, rare primary liver
neoplasms, rare primary bile duct neoplasms.
7.10. New evolving fields for liver biopsy: Liver transplantation, Bone marrow
transplantation, Living donors and Morbid obesity
7.10.1. Liver transplantation
With regards to liver transplantation, liver biopsy remains very useful in the management of
transplanted patients. In this clinical situation, if a rejection is suspected and other complica‐
tions have been ruled out, a guided biopsy will be performed. This procedure can be of
great value in order to confirm the specific diagnosis and to indicate treatment [104].
In the first few weeks and months after transplantation, the major causes of abnormal liver
tests include preservation injury, acute rejection, opportunistic infections (e.g., cytomegalo‐
virus, hepatitis), vascular compromise, and/or biliary stricture. Of these, acute allograft re‐
jection is the most common and results from direct alloantigenic stimulation of recipient T
cells by donor dendritic cells (antigen-presenting cells). The effector T cells can then prefer‐
entially injure biliary epithelial cells of both interlobular and septal bile ducts as well as en‐
dothelial cells of intrahepatic arteries and veins.
The main histological features of acute rejection Acute rejection is characterized by an infiltration
of mixed, predominantly mononuclear cells within portal tracts. The inflammatory infil‐
trates include lymphocytes, macrophages, plasma cells, polymorphonuclear neutrophils and
eosinophils. The inflammatory cells typically infiltrate the bile duct epithelium and are asso‐
ciated with bile duct damage. Subendothelial inflammation (endothelialitis), which may in‐
volve both portal and central veins, is also a typical feature. The most common grading
system is the Banff schema, a consensus document proposed by an international panel of
pathologists and liver transplant physicians [105]. Criteria helping to distinguish recurrent
hepatitis C after transplantation from allograft rejection; Hepatitis C (HCV) recurs in virtual‐
ly all patients transplanted for that disease.
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Distinguishing recurrent hepatitis from acute allograft rejection, which can overlap, is diffi‐
cult. There are usually three main phases to recurrent HCV:
• Graft reinfection (from 0 to 3 months post-transplant). HCV-related inflammation is rare‐
ly seen at this time. Liver biopsies may show mild lobular disarray, few necrotic hepato‐
cytes (acidophil bodies), and fatty change.
• Established graft infection (from 3 to 6 months), acute hepatitis including ballooning de‐
generation of hepatocytes, acidophil bodes, and Kupffer cell prominence can be observed.
Varying degrees of portal tract inflammation may also be present.
• Progressive liver damage (after 6 months), features related to chronic HCV infection such
as, mononuclear portal infiltrates and interface hepatitis are observed. Bile duct damage,
although mild, may occur, and granulomas may be detected. Up to half of patients will
have histological evidence after 1 year.
The role of liver biopsy in the evaluation of abnormal liver tests after the first year post transplanta‐
tion Common causes after the first year include acute rejection, opportunistic infection, re‐
current viral hepatitis, chronic rejection, steatohepatitis, or recurrent diseases. Chronic
rejection occurs as a consequence of repeated episodes of acute rejection that are unrespon‐
sive to immunosuppression. The main histological abnormalities are loss of small bile ducts
(ductopenic rejection) and/or obliterative vasculopathy (affecting large and medium-sized
arteries). Unlike acute allograft rejection, the degree of bile duct damage is typically out of
proportion to the degree of inflammation.
Complications of liver transplantation are not limited to acute and chronic rejection and re‐
currence of original disease, but include surgical complications, most commonly hepatic ar‐
tery occlusion, infections, and development of de novo malignancies. In the early post
transplantation period preservation injury, damage to the graft during harvesting and im‐
plantation, may lead to significant graft dysfunction. In post-perfusion biopsies, heavy neu‐
trophilic infiltrate and hepatocyte necrosis may be predictive of initial poor graft function.
Ischemic complications, such as hepatic artery thrombosis, are one of the most serious com‐
plications and may lead to early graft loss or biliary stricture. In these patients liver biopsy is
usually not performed.
Infectious complications that generally occur after transplantation, cytomegalovirus(CMV)
for example, remains common and is frequently associated with parenchymal microabscess‐
es which are found in the liver biopsy of CMV patients.
7.10.2. Bone marrow transplantation
A liver biopsy is effective in the evaluation of a bone marrow transplant recipient with ele‐
vated liver tests [106]. Known complications of bone marrow transplantation include veno-
occlusive disease (VOD) and graft-versus-host disease (GVHD). A biopsy is necessary to
diagnose VOD. It develops within 1 to 4 weeks after transplantation and is characterized by
occlusion of central veins, sinusoidal fibrosis, and pericentral hepatocyte necrosis. Acute
GVHD develops within 6 weeks after transplantation and affects the skin, gastrointestinal
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tract, and liver. It is characterized by degenerative bile duct lesions with some degree of
mononuclear inflammation. Cholestasis may be present. Chronic GVHD is a multiorgan
process that develops 80 to 400 days after transplantation and is often preceded by acute
GVHD. The changes in the liver are similar to those in acute disease, but the ducts show
more prominent changes and are likely to be reduced in number or destroyed. A prominent
periportal mononuclear infiltrate, or even piecemeal necrosis, may be seen.
7.10.3. Liver transplant living donor
Liver biopsies detect silent donor disease in potential living liver donors, especially patients
suffering subclinical non-alcoholic fatty liver disease (NAFLD). The contribution of liver bi‐
opsy or even the need to perform this, when a potential donor is being evaluated is a contro‐
versial issue [107]. In the University of Pittsburgh Medical Center a retrospective study of the
histopathologic examination and diagnoses of 284 patients, who were evaluated as living do‐
nors from 2001 to 2005 was carried out. Hepatic histology was correlated with liver injury
tests and with demographic characteristics in an otherwise normal healthy population. A mi‐
nority  (n=119;  42%)  of  biopsies  from this  population  of  143  males/141  females  (average
age=36.8years; mean BMI=26.6) were completely normal. The remainder showed steatosis
(n=107; 37%), steatohepatitis (n=44; 15%), or unexplained low-grade/early stage chronic hepa‐
titis, primary biliary cirrhosis, or nodular regenerative hyperplasia (n=16; 6%). Biopsy find‐
ings disqualified 29/56 donors, negative factors were: obesity, age and liver iron content,
contributing to NAFLD pathogenesis. The conclusion was that liver biopsy provides valuable
information about otherwise undetectable liver disease in potential liver donors.
7.10.4. Morbid obesity
About 90 per cent of morbidly obese patients show histological abnormalities of the liver.
Morbid  obesity  may  lead  to  severe  disease  showing  steatosis,  ballooning  degeneration,
lobular inflammation and fibrosis in the study of liver biopsy. These features are similar
to the lesions observed in alcoholic hepatitis  and may end in cirrhosis and liver failure.
Many factors such as, alcohol, drugs, diabetes, viruses, can contribute to progressive liver
damage. The development of severe fatty liver disease may be asymptomatic showing a
poor correlation with liver function tests. It  has been reported that after bypass surgery,
weight loss is accompanied by improvement in fatty change and the liver function tests
are normal.
Histopathologic findings in the liver of 160 patients who were undergoing laparoscopic gas‐
tric bypass or gastric banding for morbid obesity, were recorded, also clinical data (gender,
age, BMI and associated diseases) and laboratory evaluation were obtained [108].The diag‐
nosis obtained were : 63 non-nonalcoholic steatohepatitis (non-NASH), 54 NASH, 26 chronic
hepatitis B (CHB), 15 alcoholic steatohepatitis and NASH, and 2 chronic hepatitis C
(CHC).The coexistence of clinical and histological features of steatohepatitis with another
chronic liver disease may reflect the biological significance of the chronic inflammatory con‐
dition in the obese population, which requires further investigation.
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8. Non-invasive tests for liver disease and assessment of fibrosis and
cirrhosis
Limitations  of  biopsy have led clinical  investigators  to  study alternative  methods to  in‐
vestigate  liver  disease  especially  for  the  assessment  of  liver  fibrosis.  Since  fibrosis  is  of
sufficient  importance in chronic  liver disease and because it  progresses to cirrhosis  it  is
frequently  used as  the  outcome and prognostic  variable  in  clinical  studies.  Hepatic  fib‐
rosis  is  currently  viewed  as  a  dynamic  process  that  may  regress  after  successful  treat‐
ment  of  chronic  liver  diseases.  Serum  markers,  such  as  non-invasive  markers,  offer  an
attractive  alternative.  They are  objective,  allowing a  dynamic  calibration of  fibrosis,  can
be performed repeatedly,  are more cost  effective and many of them are performed as a
routine analysis [109].
Indirect markers of liver fibrosis:  among them, the AST to Platelet Ratio Index (APRI),
combines  aspartate  amiotransferase  (AST)  with  platelet  count.  It  was  used  in  several
studies conducted in cohorts of  patients with hepatitis  C and showed a rather good di‐
agnostic  performance and reproducibility,  [110]  particularly for  cirrhosis.  Forns and col‐
leagues  reported  a  fibrosis  index  (Forns’  index)  based  on  platelet  count,  γ-glutamyl
transferase (GGT), and cholesterol levels [111]. It is rather good for excluding significant
fibrosis,  but  only  average  for  diagnosing  significant  fibrosis.  However,  one  important
limit  of  both  APRI  and  Forns’  indexes  are  that  they  leave  almost  half  of  the  patients
unclassified.
Another widely investigated combination set of noninvasive markers of liver fibrosis is the
Fibrotest; a combination of five blood tests based on a mathematical formula: GGT, biliru‐
bin, haptoglobin, apolipoprotein A1, alfa2 macroglobulin adjusted for gender and age. Ac‐
cording to the investigators, it could exclude cases with significant fibrosis (METAVIR > F2),
having 100% of negative predictive value, and more than 90% positive predictive value, us‐
ing liver biopsy as a reference [112].
8.1. Elastography (FibroScan)
Another  noninvasive  method for  the  assessment  of  liver  fibrosis  is  elastography (Fibro‐
Scan) [113].
FibroScan device (EchoSens, Paris, France) uses a mild-amplitude, low frequency vibration
transmitted through the liver. It induces an elastic shear wave that is detected by pulse-echo
ultrasonography as the wave propagates through the organ. The velocity of the wave corre‐
lates with tissue stiffness which correlates well with the degree of fibrosis.
This device is in widespread use in many parts of the world, but is not yet approved in the
United States.
Most of the studies have been conducted on patients with chronic hepatitis C but a few
studies have also covered fibrosis and cirrhosis due to other etiologies.
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This technique, however, has its limitations: it uses expensive equipment, and has decreased
accuracy in obese patients and in patients with ascites. Elastography results are not valid in
presence of hepatic steatosis, cholestasis, necroinflammation, or portal hypertension. The
patient’s age and levels of aminotransferases need to be taken into account when interpret‐
ing results of liver stiffness [114].
IN FAVOUR of LIVER BIOPSY AGAINST OF LIVER BIOPSY
Chronic HCV hepatitis In selected indications for grading and
staging
Not necessary for diagnosis. Possible
use of non-invasive methods in follow-
up controls
Chronic HBV hepatitis Grading and staging advisable before
starting treatment
Not necessary for diagnosis. Possible
use of non-invasive methods in follow-
up controls
Non-alcoholic steatohepatitis (NASH) NASH is a always an histopathological
diagnosis
Assessment of fibrosis possible with
non-invasive methods
Alcoholic steatohepatitis (ASH) ASH is a histopathological diagnosis.
But in alcoholic acute hepatitis liver
biopsy usually is not performed
Assessment of fibrosis possible with
non-invasive methods,( in abstinent
patients)
Autoimmune Hepatitis For diagnosis and staging liver biopsy is
needed
Non validated methods yet for non-
invasive assessment of fibrosis
Primary Biliary Cirrhosis (PBC) Not needed in typical mild cases
without biliary duct damage
Possible non-invasive assessment of
fibrosis
Hemochromatosis In general, liver biopsy performed for
diagnosis and staging, and iron
content in the liver
Non validated methods for non-
invasive assessment of fibrosis
Wilson disease For diagnosis and staging and copper
content in the liver
Non other options
Table 5. Indication for liver biopsy in different chronic liver diseases in the era of non-invasive methods
In spite of that, elastography is complementary as the combination of noninvasive markers
and elastography improves the overall accuracy. In one of the metanalysis, for significant
fibrosis, the area under the ROC for Fibrotest and FibroScan were 0.81 (95% CI 0.78-84) and
0.83 (0.03-1.00), respectively [115].
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Fibrotest, and elastography (Fibroscan) as first line estimates of fibrosis in patients with
chronic hepatitis C are recommended and liver biopsy will probably be indicated only as a
second line diagnosis and reserved for cases of discordance or non-interpretability [112].
Some  authors  conclude  that  elastography  appears  reliable  to  detect  significant  fibrosis
and cirrhosis in patients with chronic hepatitis C, besides it may turn out to be a valua‐
ble diagnostic  procedure and follow-up of  patients  with chronic liver diseases of  differ‐
ent causes [115].
8.2. Liver biopsy: Consensus among pathologists?
It  is  crucial that biopsy interpretation be done by experienced liver pathologists.  Pathol‐
ogists  have  tried  to  define  the  features  (including length  and number  of  complete  por‐
tal  tracts)  of  an  adequate  liver  biopsy  sample  able  to  correctly  assess  the  classification
of  liver  fibrosis.  Some authors  have  recommended big  samples  of  1  to  4  cm in  length
containing at  least  11 complete portal  tracts,  which could be more reliable for adequate
grading and staging [116, 117]
Feature Effect on response to therapy Effect on natural history
Fibrosis Reduces response Presence implies progression
Inflammation No effect Related to increased amount of current
fibrosis and increased rate of
progression
Steatosis Reduces response Related to increased amount of current
fibrosis, unclear effect on progression
Iron accumulation Unclear effect Related to increased amount of current
fibrosis, unclear effect on prospective
rate
(adapt from Semin Liver Dis 2005)
Table 6. Relevance of histological features of chronic hepatitis C to disease progression and therapeutic response
Many intraobserver  and interobserver  variations  have been estimated in  the  assessment
of features, classification, and scoring of liver biopsy assessment. One study reported dif‐
ferences in the evaluation of liver biopsies in chronic viral hepatitis C among 10 patholo‐
gists  specializing  in  liver  diseases.  These  pathologists  independently  reviewed  30  liver
biopsy specimens of  viral  hepatitis  C and completed a histological  form for each of  the
specimens.  Five  pairs  of  pathologists  were  then  randomly  designated  and  they  inde‐
pendently reviewed the biopsy specimens and filled out  a  new coding form. The inter‐
observer  variation  was  calculated  for  each  item  among  the  10  individuals  and  then
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among the five pairs.  Five features showed an almost perfect  or a substantial  degree of
concordance among the  10  observers  (cirrhosis,  fibrosis,  fibrosis  grading by Knodell  in‐
dex, steatosis and portal lymphoid aggregates).  The 17 other indicators showed a weak‐
er  concordance.  Five  items  had  a  higher  concordance  when  viewed  by  a  pair  of
pathologists  than  when  studied  by  only  one  pathologist  (steatosis,  periportal  necrosis
grading by Knodell index, lobular necrosis grading by Knodell index, centrilobular fibro‐
sis,  and ductular  proliferation).  This  study reveals  that  certain  features  of  major  impor‐
tance  in  assessing  disease  activity  show  significant  observer  variation.  The  acceptable
degree of concordance was related mainly to the fibrosis score, whereas other numerical
items displayed substantial observer variations. Simultaneous observation by two pathol‐
ogists  increased the reproducibility of  numerical  scoring and of  certain viral  hepatitis  C
lesions.  A classification of  chronic  hepatitis  C based on dissociated semiquantitative  as‐
sessment  of  necroinflammatory lesions  and fibrosis  offers  more reproducibility  than the
use of a global numerical index [107].
As a single percutaneous liver biopsy yields only a minute percentage (1 ⁄ 50 000 or 0.002%)
of the total hepatic tissue, paired biopsies have been evaluated in several published studies,
especially for assessing steatosis and NASH. For quantification, better references are re‐
quired, such as imaging techniques or morphometry, which determines the area of steatosis
on liver biopsy.
In fact, as liver steatosis is not homogeneous, classical optical examination of a liver biopsy
by a pathologist for measuring liver steatosis by the determination of the percentage of hep‐
atocytes containing lipid vesicles is highly subjective, and steatosis grading corresponds on‐
ly to a semiquantitative scale [68].
The role of the liver biopsy in disease management is evolving nowadays and has to be re‐
considered given the modern pathologic assessment of liver biopsy. Pathologists have made
progress in the interpretation of liver biopsies and in processing the information in a concise
and scientific way available to clinicians. After evaluating the disease state and interpreting
the tests results, the clinician in charge of the patient should consider the individual patient
when making recommendations with regards to treatment.
Role of the liver biopsy in personalized medicine
The liver biopsy specimen aims to obtain a valuable material for the assessment of fibrosis
and cirrhosis. Despite limitations related to sampling and interpretation, histological exami‐
nation remains the best standard for staging and diagnosing chronic liver diseases. Its indi‐
cations are decreasing because new therapeutical options for chronic viral hepatitis have
improved [118]. Moreover, new non-invasive tests have been developed and their use may
increase in the future, especially for long term management [119] (Table 7).
All invasive procedures involve risks, consequently the benefits of obtaining liver for histol‐
ogy should always be weighed against the possible morbidity of the procedure. The deci‐
sion to indicate a liver biopsy has to be taken depending on the center’s facilities and the
availability of experienced liver pathologists to interpret the biopsy.
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Ethics related to liver biopsy mainly include issues on the indications, information on poten‐
tial risks and benefits and validity of available alternative options. Patients should be ade‐
quately informed and participate in the decisions for liver biopsy and treatment [120].
Liver biopsy Transient elastography
Advantages - Direct measure of liver fibrosis
- Well established staging system
- Assessment of architectural
disturbances related to liver fibrosis
- Evaluation of associated lesions
(inflammation, steatosis, iron, alcohol)
- Non-invasive
- Easy to repeat
- No risk to patient
- Performed in the outpatient clinic
- Results available immediately
- Reproducible
- Highly performance for detecting
cirrhosis
Disadvantages - Invasive and painful
- Difficult to repeat
- Potentially severe complications
- Contraindicated if ascites,
coagulopathy etc.
- Sampling and interobserver variability
- Unable to discriminate between
intermediate stages of fibrosis
- False positive in case of acute
hepatitis, extrahepatic cholestasis and
congestive heart failure
(adapt L Castera & M Pinzani, Gut 2010)
Table 7. Use of liver biopsy in clinical practice. Respective advantages and disadvantages of liver biopsy and transient
elastography for assessing fibrosis in chronic liver disease
12. Conclusions
What will be the real impact of Liver Biopsy now and in the near future in the era of person‐
alized medicine?
1. The practice of liver biopsy will remain as an important component in the evaluation of
liver disease. However, the value of liver biopsy should be contemplated as a comple‐
mentary tool in modern medicine because of the presence of new non-invasive diagnos‐
tic measures, better prognostication methods and more advances in imaging
techniques.
2. Non invasive tests such as Fibroscan, or similar, adding serum markers will be increas‐
ingly used to identify the amount of fibrosis, and will spare, in most patients, the per‐
formance of a liver biopsy.
3. Liver biopsy provides information that is used in conjunction with other data to inform
and to guide therapy. The team that joins pathologists, clinicians, radiologists and other
specialists meets in order to make clinico-pathological correlations. New classifications
incorporating clinical data in the histological dictamen will be implemented.
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4. Therapies, etiology, pathogenesis, cellular and molecular mechanisms, changes in tissue
architecture and invasive (HVPG) and noninvasive diagnostic approaches, should be
added to the liver biopsy information.
5. In the liver transplant field, liver biopsy has allowed many scientific advances and in
most of these patients liver biopsy will continue to be mandatory for their management.
6. Patients seeking a second opinion or who are referred to a tertiary care center, will re‐
quire a deep review of previous obtained specimens in order to confirm and to plan
their management.
7. Since chronic viral hepatitis is a prevalent disease in the general population, the number
of liver biopsies will be limited in the next years because it is costly and aggressive so
validated non-invasive methods will be favoured.
8. Nevertheless, some questions surrounding non-invasive markers will remain. Non-in‐
vasive markers have been validated against the biopsy, and the overall accuracy of bi‐
opsy is only 80%, it is probably statistically impossible for a marker to perform any
better than a biopsy.
9. Increasing research on hepatic fibrosis, diagnoses and therapy, is ongoing so valuable
results of predicting changes in fibrosis content over time have to be followed by histo‐
logical liver assessment. Moreover, considering the possible regression of cirrhosis, now
clinicians and pathologists have become more interested in studying histological fea‐
tures of tissue repair and fibrosis regression in the liver.
10. The number of liver biopsy will be sparing in common patients but it will play a crucial
role in research; for example studying rare diseases, stem cells and genetic disorders.
Moreover, its role is evolving in many research fields such as obesity, bone marrow
transplant, and oncology.
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